Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Blood
|
August 1, 1983
Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia
J Gmür, A von Felten, B Osterwalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine
D R Budman, N J Meropol, B Reigner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
J L Blum, S E Jones, A U Buzdar, et al.
British Journal of Cancer
|
May 3, 2002
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
D C Talbot, V Moiseyenko, S Van Belle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
E Van Cutsem, M Findlay, B Osterwalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study
P M Hoff, R Ansari, G Batist, et al.
Schweizerische Medizinische Wochenschrift
|
November 24, 1998
[25 years allogenic bone marrow transplantation in Basel: 1973-1998]
J R Passweg, A Gratwohl, A Tichelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy, C Twelves, E Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study
E Van Cutsem, C Twelves, J Cassidy, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Blood
|
August 1, 1983
Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia
J Gmür, A von Felten, B Osterwalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine
D R Budman, N J Meropol, B Reigner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
J L Blum, S E Jones, A U Buzdar, et al.
British Journal of Cancer
|
May 3, 2002
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
D C Talbot, V Moiseyenko, S Van Belle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
E Van Cutsem, M Findlay, B Osterwalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study
P M Hoff, R Ansari, G Batist, et al.
Schweizerische Medizinische Wochenschrift
|
November 24, 1998
[25 years allogenic bone marrow transplantation in Basel: 1973-1998]
J R Passweg, A Gratwohl, A Tichelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy, C Twelves, E Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study
E Van Cutsem, C Twelves, J Cassidy, et al.
Page
of 7